NYSE:RMD ResMed (RMD) Stock Forecast, Price & News $215.44 -1.53 (-0.71%) (As of 05/26/2023 07:00 PM ET) Add Compare Share Share Today's Range$214.79▼$218.4450-Day Range$210.59▼$240.9652-Week Range$194.30▼$247.65Volume698,700 shsAverage Volume595,124 shsMarket Capitalization$31.65 billionP/E Ratio36.70Dividend Yield0.82%Price Target$263.43 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ResMed MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside22.3% Upside$263.43 Price TargetShort InterestHealthy0.71% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-0.55Upright™ Environmental ScoreNews Sentiment0.76Based on 9 Articles This WeekInsider TradingSelling Shares$7.14 M Sold Last QuarterProj. Earnings Growth12.04%From $6.48 to $7.26 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector74th out of 1,010 stocksSurgical & Medical Instruments Industry7th out of 104 stocks 2.4 Analyst's Opinion Consensus RatingResMed has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $263.43, ResMed has a forecasted upside of 22.3% from its current price of $215.44.Amount of Analyst CoverageResMed has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.71% of the outstanding shares of ResMed have been sold short.Short Interest Ratio / Days to CoverResMed has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ResMed has recently increased by 1.96%, indicating that investor sentiment is decreasing. Previous Next 1.7 Dividend Strength Dividend YieldResMed has a dividend yield of 0.82%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthResMed has only been increasing its dividend for 2 years.Dividend CoverageThe dividend payout ratio of ResMed is 29.98%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, ResMed will have a dividend payout ratio of 24.24% next year. This indicates that ResMed will be able to sustain or increase its dividend. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreResMed has received a 72.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Continuous positive airway pressure devices", "Diagnostics software for sleep apnea", and "Continuous sleep apnea monitoring devices" products. See details.Environmental SustainabilityThe Environmental Impact score for ResMed is -0.55. Previous Next 2.6 News and Social Media Coverage News SentimentResMed has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for ResMed this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for RMD on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows9 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,143,067.00 in company stock.Percentage Held by InsidersOnly 1.39% of the stock of ResMed is held by insiders.Percentage Held by Institutions64.73% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for ResMed are expected to grow by 12.04% in the coming year, from $6.48 to $7.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ResMed is 36.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.70.Price to Earnings Ratio vs. SectorThe P/E ratio of ResMed is 36.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.56.Price to Earnings Growth RatioResMed has a PEG Ratio of 3.23. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioResMed has a P/B Ratio of 9.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ResMed (NYSE:RMD) StockResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.Read More Receive RMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter. Email Address RMD Stock News HeadlinesMay 29, 2023 | americanbankingnews.comResMed (NYSE:RMD) Cut to Hold at StockNews.comMay 25, 2023 | finanznachrichten.deResMed Inc.: 3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023May 29, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 24, 2023 | americanbankingnews.comResMed (NYSE:RMD) Now Covered by UBS GroupMay 23, 2023 | americanbankingnews.comAnalysts Set ResMed Inc. (NYSE:RMD) Target Price at $259.00May 22, 2023 | msn.comUBS Initiates Coverage of Resmed (RMD) with Buy RecommendationMay 20, 2023 | americanbankingnews.comMichael J. Farrell Sells 5,675 Shares of ResMed Inc. (NYSE:RMD) StockMay 17, 2023 | americanbankingnews.comResMed Inc. (NYSE:RMD) COO Robert Andrew Douglas Sells 1,500 SharesMay 29, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 16, 2023 | americanbankingnews.comFY2023 EPS Estimates for ResMed Inc. (NYSE:RMD) Raised by AnalystMay 13, 2023 | americanbankingnews.comInsider Selling: ResMed Inc. (NYSE:RMD) CFO Sells $795,003.30 in StockMay 11, 2023 | americanbankingnews.comResMed (NYSE:RMD) Raised to "Buy" at StockNews.comMay 8, 2023 | americanbankingnews.comResMed Inc. (RMD) to Issue Quarterly Dividend of $0.44 on June 15thMay 7, 2023 | americanbankingnews.comInsider Selling: ResMed Inc. (NYSE:RMD) Insider Sells $356,460.00 in StockMay 3, 2023 | americanbankingnews.comResMed Inc. (NYSE:RMD) Insider Sells $119,650.00 in StockMay 3, 2023 | americanbankingnews.comResMed Inc. (NYSE:RMD) Expected to Post Q4 2023 Earnings of $1.64 Per ShareMay 2, 2023 | americanbankingnews.comResMed Inc. Forecasted to Earn FY2023 Earnings of $6.53 Per Share (NYSE:RMD)April 28, 2023 | americanbankingnews.comBrokerages Set ResMed Inc. (NYSE:RMD) Target Price at $259.00April 27, 2023 | seekingalpha.comResMed Inc. 2023 Q3 - Results - Earnings Call PresentationApril 27, 2023 | americanbankingnews.comKaushik Ghoshal Sells 2,000 Shares of ResMed Inc. (NYSE:RMD) StockApril 25, 2023 | americanbankingnews.comResMed (RMD) Set to Announce Earnings on ThursdayApril 20, 2023 | americanbankingnews.comResMed Inc. (NYSE:RMD) COO Sells $336,975.00 in StockApril 14, 2023 | americanbankingnews.comMizuho Initiates Coverage on ResMed (NYSE:RMD)April 13, 2023 | seekingalpha.comResMed Gives Investors A Good Night's SleepApril 6, 2023 | finance.yahoo.comResMed Inc.'s (NYSE:RMD) Stock Been Rising: Are Strong Financials Guiding The Market?April 6, 2023 | americanbankingnews.comInsider Selling: ResMed Inc. (NYSE:RMD) Insider Sells 1,500 Shares of StockApril 3, 2023 | americanbankingnews.comResMed Inc. (NYSE:RMD) Receives $263.17 Consensus Price Target from AnalystsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter. Email Address RMD Company Calendar Ex-Dividend for 3/16 Dividend2/08/2023Dividend Payable3/16/2023Last Earnings4/27/2023Ex-Dividend for 6/15 Dividend5/10/2023Today5/29/2023Dividend Payable6/15/2023Fiscal Year End6/30/2023Next Earnings (Estimated)8/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:RMD CUSIP76115210 CIK943819 Webwww.resmed.com Phone(858) 836-5000Fax858-836-5501Employees8,160Year Founded1989Price Target and Rating Average Stock Price Forecast$263.43 High Stock Price Forecast$290.00 Low Stock Price Forecast$245.00 Forecasted Upside/Downside+22.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$5.87 Trailing P/E Ratio36.70 Forward P/E Ratio33.25 P/E Growth3.23Net Income$779.44 million Net Margins21.49% Pretax Margin26.47% Return on Equity25.82% Return on Assets15.78% Debt Debt-to-Equity Ratio0.40 Current Ratio3.07 Quick Ratio1.74 Sales & Book Value Annual Sales$3.58 billion Price / Sales8.85 Cash Flow$7.14 per share Price / Cash Flow30.17 Book Value$22.97 per share Price / Book9.38Miscellaneous Outstanding Shares146,930,000Free Float144,889,000Market Cap$31.65 billion OptionableOptionable Beta0.48 Social Links Key ExecutivesMick FarrellChairman & Chief Executive OfficerRob DouglasPresident & Chief Operating OfficerBrett A. SandercockChief Financial OfficerCarlos M. NunezChief Medical OfficerUrvashi TyagiChief Technology OfficerKey CompetitorsBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDDexComNASDAQ:DXCMTeleflexNYSE:TFXBecton, Dickinson andNYSE:BDXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 3,062 shares on 5/26/2023Ownership: 0.016%Toroso Investments LLCBought 228 shares on 5/23/2023Ownership: 0.002%Seaport Global Advisors LLCSold 357 shares on 5/23/2023Ownership: 0.001%Ameriprise Financial Inc.Sold 33,487 shares on 5/22/2023Ownership: 0.051%American TrustSold 829 shares on 5/22/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions RMD Stock - Frequently Asked Questions Should I buy or sell ResMed stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RMD shares. View RMD analyst ratings or view top-rated stocks. What is ResMed's stock price forecast for 2023? 9 analysts have issued 12 month price targets for ResMed's shares. Their RMD share price forecasts range from $245.00 to $290.00. On average, they expect the company's share price to reach $263.43 in the next year. This suggests a possible upside of 22.3% from the stock's current price. View analysts price targets for RMD or view top-rated stocks among Wall Street analysts. How have RMD shares performed in 2023? ResMed's stock was trading at $208.13 at the beginning of the year. Since then, RMD stock has increased by 3.5% and is now trading at $215.44. View the best growth stocks for 2023 here. When is ResMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RMD earnings forecast. How were ResMed's earnings last quarter? ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, April, 27th. The medical equipment provider reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.10. The medical equipment provider earned $1.12 billion during the quarter, compared to analyst estimates of $1.05 billion. ResMed had a net margin of 21.49% and a trailing twelve-month return on equity of 25.82%. The company's quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 earnings per share. Read the conference call transcript. How often does ResMed pay dividends? What is the dividend yield for ResMed? ResMed declared a quarterly dividend on Thursday, April 27th. Investors of record on Thursday, May 11th will be given a dividend of $0.44 per share on Thursday, June 15th. This represents a $1.76 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Wednesday, May 10th. Read our dividend analysis for RMD. What ETFs hold ResMed's stock? ETFs with the largest weight of ResMed (NYSE:RMD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Motley Fool Mid-Cap Growth ETF (TMFM), Fidelity Digital Health ETF (FDHT), Simplify Health Care ETF (PINK), Emerge EMPWR Sustainable Select Growth Equity ETF (EMGC), iShares U.S. Medical Devices ETF (IHI), BlackRock Future Health ETF (BMED) and Capital Group Global Growth Equity ETF (CGGO). Is ResMed a good dividend stock? ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.82%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 29.98%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.24% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RMD. What is Mick Farrell's approval rating as ResMed's CEO? 284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ResMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM). What is ResMed's stock symbol? ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD." Who are ResMed's major shareholders? ResMed's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.94%), FMR LLC (4.42%), State Street Corp (4.28%), WCM Investment Management LLC (2.37%), Geode Capital Management LLC (2.20%) and Ownership Capital B.V. (0.95%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor. View institutional ownership trends. How do I buy shares of ResMed? Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ResMed's stock price today? One share of RMD stock can currently be purchased for approximately $215.44. How much money does ResMed make? ResMed (NYSE:RMD) has a market capitalization of $31.65 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.87 on an earnings per share basis. How many employees does ResMed have? The company employs 8,160 workers across the globe. Does ResMed have any subsidiaries? The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.Read More How can I contact ResMed? ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501. This page (NYSE:RMD) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.